COMPANY BACKGROUND GondolaBio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, a subsidiary of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. The company aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology.
Located on the Stanford Life Sciences campus, GondolaBio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation. To learn more, visit us at gondolabio.com Who You Are Putting patients first is a core value of GondolaBio. We are committed to engaging patients, families, caregivers, and community advocates throughout the drug development process to understand their experiences, challenges, and priorities and incorporate their perspectives into our work.
Reporting to the Head of Patient Advocacy, the Senior Manager, Patient Advocacy will serve as a patient advocacy partner across GondolaBio's development portfolio. This individual will develop deep knowledge of assigned disease areas and patient communities, build productive and enduring relationships with patient advocacy organizations and community leaders, and work closely with development teams to ensure patient perspectives inform our work.
The Senior Manager will support multiple programs at different stages of development, including providing advocacy leadership to programs that may not have dedicated
Job details are sourced from the employer's original posting.
Open job postingAbout the company
This company is involved in clinical pharmacology and early clinical development, focusing on early clinical sciences and development strategy from first-in-human through Phase 2. They also lead quantitative sciences including data analytics, pharmacometrics, biostatistics, and data management to inform dose selection and program development.